1887

Abstract

Human papillomavirus type 16 (HPV-16)-associated vulval intraepithelial neoplasia (VIN) is frequently a chronic, multifocal high-grade condition with an appreciable risk of progression to vulval cancer. The requirement to treat women with VIN has recently stimulated the use of immunotherapy with E6/E7 oncogene vaccines. Animal models have shown that E2 may also be a useful vaccine target for HPV-associated disease; however, little is known about E2 immunity in humans. This study investigated the prevalence of HPV-16 E2-specific serological and T-cell responses in 18 women with HPV-16-associated VIN and 17 healthy volunteers. E2 responses were determined by full-length E2–GST ELISA with ELISPOT and proliferation assays using E2 C-terminal protein. As positive controls, HPV-16 L1 responses were measured using virus-like particles (VLPs) and L1–GST ELISA with ELISPOT and proliferation using VLPs as antigen. The VIN patients all showed a strong serological response to L1 compared with the healthy volunteers by VLP (15/18 vs 1/17, <0·001) and L1–GST ELISA (18/18 vs 1/17, <0·001). In contrast, L1-specific cellular immune responses were detected in a significant proportion of controls but were more prevalent in the VIN patients by proliferation assay (9/17 vs 17/18, <0·02) and interferon- ELISPOT (9/17 vs 13/18, =not significant). Similar and low numbers of patients and controls were seropositive for E2-specific Ig (2/18 vs 1/17). In spite of previous studies showing the immunogenicity of E2 in eliciting primary T-cell responses , there was a low prevalence of E2 responses in the VIN patients and controls (2/18 vs 0/17).

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19095-0
2003-08-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/8/vir842089.html?itemId=/content/journal/jgv/10.1099/vir.0.19095-0&mimeType=html&fmt=ahah

References

  1. Bauer, H. M., Greer, C. E. & Manos, M. M. ( 1992; ). Determination of genital human papillomavirus infection by consensus PCR amplification. In Diagnostic Molecular Pathology: a Practical Approach, vol. II, pp. 131–152. Edited by C. S. Herrington & J. O. D. McGee. Oxford: Oxford University Press.
  2. Bontkes, H. J., de Gruijl, T. D., Bijl, A. & 7 other authors ( 1999; ). Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 80, 2453–2459.
    [Google Scholar]
  3. Borysiewicz, L. K., Fiander, A., Nimako, M. & 10 other authors ( 1996; ). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523–1527.[CrossRef]
    [Google Scholar]
  4. Carter, J. J., Koutsky, L. A., Wipf, G. C., Christensen, N. D., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. ( 1996; ). The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174, 927–936.[CrossRef]
    [Google Scholar]
  5. Davidson, E. J., Brown, M. D., Burt, D. J., Parish, J. L., Gaston, K., Kitchener, H. C., Stacey, S. N. & Stern, P. L. ( 2001; ). Human T cell responses to HPV-16 E2 generated with monocyte-derived dendritic cells. Int J Cancer 94, 807–812.[CrossRef]
    [Google Scholar]
  6. de Jong, A., van der Burg, S. H., Kwappenberg, K. M. & 9 other authors ( 2002; ). Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62, 472–479.
    [Google Scholar]
  7. De Roda Husman, A. M., Walboomers, J. M. M., van den Brule, A. J. C., Meijer, C. J. L. M. & Snijders, P. J. F. ( 1995; ). The use of general primers Gp5 and Gp6 elongated at their 3′ ends with adjacent highly conserved sequences improves papillomavirus detection by PCR. J Gen Virol 76, 1057–1062.[CrossRef]
    [Google Scholar]
  8. Dillner, J., Lenner, P., Lehtinen, M., Eklund, C., Heino, P., Wiklund, F., Hallmans, G. & Stendahl, U. ( 1994; ). A population-based seroepidemiological study of cervical cancer. Cancer Res 54, 134–141.
    [Google Scholar]
  9. Graham, D. A. & Herrington, C. S. ( 2000; ). HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. Mol Pathol 53, 201–206.[CrossRef]
    [Google Scholar]
  10. Hamsikova, E., Novak, J., Hofmannova, V., Munoz, N., Bosch, F. X., de Sanjose, S., Shah, K., Roth, Z. & Vonka, V. ( 1994; ). Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 170, 1424–1431.[CrossRef]
    [Google Scholar]
  11. Han, R., Cladel, N. M., Reed, C. A., Peng, X., Budgeon, L. R., Pickel, M. & Christensen, N. D. ( 2000a; ). DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 74, 9712–9716.[CrossRef]
    [Google Scholar]
  12. Han, R., Reed, C. A., Cladel, N. M. & Christensen, N. D. ( 2000b; ). Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 18, 2937–2944.[CrossRef]
    [Google Scholar]
  13. Heino, P., Dillner, J. & Schwartz, S. ( 1995; ). Human papillomavirus type-16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology 214, 349–359.[CrossRef]
    [Google Scholar]
  14. Herod, J. J. O., Shafi, M. I., Rollason, T. P., Jordan, J. A. & Luesley, D. M. ( 1996; ). Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women. Br J Obstet Gynaecol 103, 446–452.[CrossRef]
    [Google Scholar]
  15. Hildesheim, A., Han, C. L., Brinton, L. A., Kurman, R. J. & Schiller, J. T. ( 1997; ). Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case–control study. Obstet Gynecol 90, 748–754.[CrossRef]
    [Google Scholar]
  16. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. & Burk, R. D. ( 1998; ). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338, 423–428.[CrossRef]
    [Google Scholar]
  17. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R. & Schiller, J. T. ( 1993; ). Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67, 6929–6936.
    [Google Scholar]
  18. Klencke, B., Matijevic, M., Urban, R. G. & 10 other authors ( 2002; ). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8, 1028–1037.
    [Google Scholar]
  19. Lehtinen, M., Leminen, A., Kuoppala, T., Tiikkainen, M., Lehtinen, T., Lehtovirta, P., Punnonen, R., Vesterinen, E. & Paavonen, J. ( 1992; ). Pre- and post-treatment serum antibody responses to HPV-16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. J Med Virol 37, 180–186.[CrossRef]
    [Google Scholar]
  20. Lenner, P., Dillner, J., Wiklund, F., Hallmans, G. & Stendahl, U. ( 1995; ). Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix. Cancer Immunol Immunother 40, 201–205.[CrossRef]
    [Google Scholar]
  21. Lenz, P., Day, P. M., Pang, Y. Y., Frye, S. A., Jensen, P. N., Lowy, D. R. & Schiller, J. T. ( 2001; ). Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166, 5346–5355.[CrossRef]
    [Google Scholar]
  22. Muderspach, L., Wilczynski, S., Roman, L. & 7 other authors ( 2000; ). A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV-16 positive. Clin Cancer Res 6, 3406–3416.
    [Google Scholar]
  23. Peitsaro, P., Johansson, B. & Syrjanen, S. ( 2002; ). Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40, 886–891.[CrossRef]
    [Google Scholar]
  24. Rocha-Zavaleta, L., Jordan, D., Pepper, S. & 7 other authors ( 1997; ). Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Brit J Cancer 75, 1144–1150.[CrossRef]
    [Google Scholar]
  25. Rozendaal, L., Walboomers, J. M. M. & Van der Linden, J. C. ( 1996; ). High risk human papillomavirus in cytomorphological normal smears has a high predictive value for development of severe dysplasia. Int J Cancer 68, 766–769.[CrossRef]
    [Google Scholar]
  26. Rudolf, M. P., Fausch, S. C., Da Silva, D. M. & Kast, W. M. ( 2001; ). Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 166, 5917–5924.[CrossRef]
    [Google Scholar]
  27. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. ( 1999; ). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [see comments]. Nature 401, 708–712.[CrossRef]
    [Google Scholar]
  28. Santin, A. D., Bellone, S., Gokden, M., Cannon, M. J. & Parham, G. P. ( 2002; ). Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346, 1752–1753.[CrossRef]
    [Google Scholar]
  29. Schiller, J. T. & Hildesheim, A. ( 2000; ). Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 19, 67–74.[CrossRef]
    [Google Scholar]
  30. Sehr, P., Zumbach, K. & Pawlita, M. ( 2001; ). A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253, 153–162.[CrossRef]
    [Google Scholar]
  31. Sehr, P., Muller, M., Hopfl, R., Widschwendter, A. & Pawlita, M. ( 2002; ). HPV- antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 106, 61–70.[CrossRef]
    [Google Scholar]
  32. Shah, K. V., Viscidi, R. P., Alberg, A. J., Helzlsouer, K. J. & Comstock, G. W. ( 1997; ). Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomark Prev 6, 233–237.
    [Google Scholar]
  33. Soler, C., Allibert, P., Chardonnet, Y., Cros, P., Mandrand, B. & Thivolet, J. ( 1991; ). Detection of human papillomavirus types 6, 11, 16 and 18 in mucosal and cutaneous lesions by the multiplex polymerase chain reaction. J Virol Methods 35, 143–157.[CrossRef]
    [Google Scholar]
  34. Steele, J. C., Roberts, S., Rookes, S. M. & Gallimore, P. H. ( 2002; ). Detection of CD4+- and CD8+-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release. J Virol 76, 6027–6036.[CrossRef]
    [Google Scholar]
  35. Stevenson, M., Hudson, L. C., Burns, J. E., Stewart, R. L., Wells, M. & Maitland, N. J. ( 2000; ). Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 81, 1825–1832.
    [Google Scholar]
  36. Sun, Y., Hildesheim, A., Brinton, L. A., Nasca, P. C., Trimble, C. L., Kurman, R. J., Viscidi, R. P. & Shah, K. V. ( 1996; ). Human papillomavirus-specific serologic response in vulvar neoplasia. Gynecol Oncol 63, 200–203.[CrossRef]
    [Google Scholar]
  37. Tindle, R. W. ( 2002; ). Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2, 59–65.[CrossRef]
    [Google Scholar]
  38. Tonon, S. A., Picconi, M. A., Bos, P. D., Zinovich, J. B., Galuppo, J., Alonio, L. V. & Teyssie, A. R. ( 2001; ). Physical status of the E2 human papillomavirus 16 viral gene in cervical preneoplastic and neoplastic lesions. J Clin Virol 21, 129–134.[CrossRef]
    [Google Scholar]
  39. van Beurden, M., ten Kate, F. J., Smits, H. L., Berkhout, R. J., de Craen, A. J., van der Vange, N., Lammes, F. B. & ter Schegget, J. ( 1995; ). Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer 75, 2879–2884.[CrossRef]
    [Google Scholar]
  40. van der Burg, S. H., Ressing, M. E., Kwappenberg, K. M. C. & 11 other authors ( 2001; ). Natural T-helper immunity against human papillomavirus type 16 (HPV-16) E7-derived peptide epitopes in patients with HPV-16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91, 612–618.[CrossRef]
    [Google Scholar]
  41. Wang, Z., Christensen, N., Schiller, J. T. & Dillner, J. ( 1997; ). A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78, 2209–2215.
    [Google Scholar]
  42. Webster, K., Parish, J., Pandya, M., Stern, P. L., Clarke, A. R. & Gaston, K. ( 2000; ). The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275, 87–94.[CrossRef]
    [Google Scholar]
  43. Wikstrom, A., Vandoornum, G. J. J., Quint, W. G. V., Schiller, J. T. & Dillner, J. ( 1995; ). Identification of human papillomavirus seroconversions. J Gen Virol 76, 529–539.[CrossRef]
    [Google Scholar]
  44. Williams, O. M., Hart, K. W., Wang, E. C. & Gelder, C. M. ( 2002; ). Analysis of CD4+ T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 76, 7418–7429.[CrossRef]
    [Google Scholar]
  45. Zhou, J., Sun, X. Y., Davies, H., Crawford, L., Park, D. & Frazer, I. H. ( 1992; ). Definition of linear antigenic regions of the HPV-16 L1 capsid protein using synthetic virion-like particles. Virology 189, 592–599.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19095-0
Loading
/content/journal/jgv/10.1099/vir.0.19095-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error